Major Depressive Disorder Drug Market Key Trends, Vendor Strategies and Industry Analysis to 2023

Major Depressive Disorder Drug In US Market Size, Share, Trends,

Company Profiles, Demand, Insights, Analysis, Research, Report,

Opportunities, Segmentation and Forecast To 2023

Summary

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide.

The MDD market is a crowded and competitive market, with more than 30 marketed products

available for the treatment of patients with MDD. The depression market is about to enter a

dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly's

Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal

antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of

seven promising late-stage pipeline products into the market during the forecast period, from

2013 to 2023.

The value of the US market is expected to fall following patent expiries for Eli Lilly's Cymbalta

in 2013, Otsuka Pharmaceutical/BMS's Abilify in 2015, and AstraZeneca's Seroquel XR in 2017.

After a period of declining sales, GlobalData estimates that the MDD market in the US will

follow a steady growth trend from 2018 to 2023.

Read Complete Report with TOC: http://www.radiantinsights.com/research/pharmapointmajor-depressive-disorder-us-drug-forecast-and-market-analysis-to-2023

Scope

- Overview of Major depressive disorder including epidemiology, etiology, symptoms, diagnosis,

pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on the key drugs in the US including product description, safety and

efficacy profiles as well as a SWOT analysis.

- Sales forecast for the top drugs in the US from 2013-2023.

- Analysis of the impact of key events as well the drivers and restraints affecting the US Major

depressive disorder market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return

- Stay ahead of the competition by understanding the...